Tscan therapeutics announces fda clearance of investigational new drug application for tsc-100 for the treatment of hematologic malignancies

– phase 1 trial of tsc-100 expected to initiate in the first half of 2022 –
TCRX Ratings Summary
TCRX Quant Ranking